title: Disruption of repressive p130-DREAM complexes by human papillomavirus 16 E6/E7 oncoproteins is required for cell-cycle progression in cervical cancer cells.
abstract: Human papillomaviruses (HPVs) with tropism for mucosal epithelia are the major aetiological factors in cervical cancer. Most cancers are associated with so-called high-risk HPV types, in particular HPV16, and constitutive expression of the HPV16 E6 and E7 oncoproteins is critical for malignant transformation in infected keratinocytes. E6 and E7 bind to and inactivate the cellular tumour suppressors p53 and Rb, respectively, thus delaying differentiation and inducing proliferation in suprabasal keratinocytes to enable HPV replication. One member of the Rb family, p130, appears to be a particularly important target for E7 in promoting S-phase entry. Recent evidence indicates that p130 regulates cell-cycle progression as part of a large protein complex termed DREAM. The composition of DREAM is cell cycle-regulated, associating with E2F4 and p130 in G0/G1 and with the B-myb transcription factor in S/G2. In this study, we addressed whether p130-DREAM is disrupted in HPV16-transformed cervical cancer cells and whether this is a critical function for E6/E7. We found that p130-DREAM was greatly diminished in HPV16-transformed cervical carcinoma cells (CaSki and SiHa) compared with control cell lines; however, when E6/E7 expression was targeted by specific small hairpin RNAs, p130-DREAM was reformed and the cell cycle was arrested. We further demonstrated that the profound G1 arrest in E7-depleted CaSki cells was dependent on p130-DREAM reformation by also targeting the expression of the DREAM component Lin-54 and p130. The results show that continued HPV16 E6/E7 expression is necessary in cervical cancer cells to prevent cell-cycle arrest by a repressive p130-DREAM complex.
authors.affiliation: Department of Molecular Medicine, University of Malaya, Kuala Lumpur, Malaysia.|Section of Virology, Department of Medicine, Imperial College London, London, UK.
authors.forename: Nurshamimi
authors.initials: N
authors.lastname: Nor Rashid
authors.affiliation: Department of Molecular Medicine, University of Malaya, Kuala Lumpur, Malaysia.
authors.forename: Rohana
authors.initials: R
authors.lastname: Yusof
authors.affiliation: Section of Virology, Department of Medicine, Imperial College London, London, UK.
authors.forename: Roger J
authors.initials: RJ
authors.lastname: Watson
mesh_terms: D002453:Cell Cycle; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D050719:Crk-Associated Substrate Protein / Q000037:antagonists & inhibitors / Q000378:metabolism*; D004847:Epithelial Cells / Q000502:physiology / Q000821:virology; D054884:Host-Pathogen Interactions; D052162:Human papillomavirus 16 / Q000472:pathogenicity*; D006801:Humans; D051605:Kv Channel-Interacting Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009856:Oncogene Proteins, Viral / Q000378:metabolism*; D050725:Papillomavirus E7 Proteins / Q000378:metabolism*; D055503:Protein Multimerization; D012097:Repressor Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*
chemical_list: C493841:BCAR1 protein, human; D050719:Crk-Associated Substrate Protein; C068651:E6 protein, Human papillomavirus type 16; C496749:KCNIP3 protein, human; D051605:Kv Channel-Interacting Proteins; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D012097:Repressor Proteins; C059731:oncogene protein E7, Human papillomavirus type 16